Biocept Inc (NASDAQ:BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, today announced that Marileila Varella Garcia, Ph.D., Professor in the Division of Medical Oncology at the University of Colorado School of Medicine, will join Biocept as a scientific advisor.

Dr. Garcia is a noted researcher in translational oncology and cytogenetic technology. She will consult with Biocept on assay development, clinical menu expansion and will assist with clinical trials for Biocept’s pharmaceutical partnerships.

One of Dr. Garcia’s primary areas of interest includes developing and validating companion diagnostic (CDx) tests, which analyze biomarkers that are used by physicians when making patient treatment decisions about whether to prescribe drugs such as Herceptin® (trastuzumab), Xalkori® (crizotinib) and Zykadia™ (ceritinib). Many of these biomarkers are included today in Biocept’s liquid biopsy test menu including ALK, HER2, ROS1, and MET.

“Dr. Garcia’s expertise in validating and developing personalized medicine assays affords us the opportunity to further expand the breadth and depth of our clinical laboratory assays, which are designed to qualify patients for existing and emerging cancer therapies based on a tumor’s genetic signature,” said Veena Singh, MD, Biocept’s Senior Vice President and Senior Medical Director. “We believe that her expertise will enhance our services when collaborating on clinical trials with potential pharmaceutical partners.”

“I am excited to collaborate with Biocept in the use of liquid biopsies for molecular diagnostic. The scientific knowledge built studying solid tumors has the opportunity to be rapidly translated to a much less invasive setting, thus bringing significant benefit to patients,” said Dr. Garcia. “Moreover, the specific features of the Biocept technical platform allow integration of different assays, which is useful for confirmation, refining results or performing complementary analyses.”

Biocept previously announced that David Rimm, MD, Ph.D., Professor of Pathology and Professor of Medicine in Medical Oncology at Yale University School of Medicine, had joined Biocept as a Scientific Advisor and is collaborating on PDL1, an important biomarker in the field of Immunotherapy.

Dr. Garcia focuses on translational cancer research using molecular cytogenetics technology. Aiming to better support molecular targeted therapies and efficiently identify patients likely to benefit from these therapies, her laboratory investigates genomic imbalances and activating fusions in metabolic pathways important in oncogenesis using fluorescence in situ hybridization (FISH)-based assays. Her laboratory not only develops new molecular reagents, but optimizes scoring systems aimed for clinical applications in specific tumor types. Dr. Garcia directs the molecular cytogenetics sections in the University of Colorado Cancer Center Molecular Pathology and in the Department of Pathology Colorado Molecular Correlates Laboratories. (Original Source)

Shares of Biocept Inc. closed last Friday at $2.38 . BIOC has a 1-year high of $5.12 and a 1-year low of $1.09. The stock’s 50-day moving average is $2.67 and its 200-day moving average is $2.64.

Biocept Inc is acancer diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, tests utilizing a standard blood sample or liquid biopsy.